A solid global foundation

Kyowa Hakko Kirin Pharma, Inc. (KKP) is a wholly owned subsidiary of Kyowa Hakko Kirin Co., Ltd., an industry leader born from the merger of Kyowa Hakko Group and Kirin Group.  Backed by six decades of its parent companies’ experience, KKP specializes in the development of new chemical entities and biopharmaceutical therapies.  Among other achievements, scientists and collaborators at KKP have leveraged advances in antibody therapeutics to make tremendous strides across key scientific fields, including oncology, immunology and nephrology.

KKP is headquartered in Princeton, New Jersey.